Table 6. KRAS mutations in primary colon carcinoma (n = 163) compared with data reported in the literature.
| Mutation | SSEQ (%) | ASLNA (%) | Literature data, % valuesa |
| G12D | 22/146 (15.1) | 27/153 (17.7) | 12.9–15.5 |
| G12V | 14/146 (9.6) | 15/153 (9.8) | 7.7–12.2 |
| G13D | 8/146 (5.5) | 10/153 (6.5) | 5–7.3 |
| G12C | 5/146 (3.4) | 7/153 (4.4) | 2.3−3.6 |
| G12A | 3/146 (2.1) | 3/153 (2.0) | 2.3–2.8 |
| G12S | 3/146 (2.1) | 4/153 (2.6) | 2.6–4.3 |
| G12R | 0/146 (0) | 3/153 (2.0) | 0.3–0.5 |
| G12F | 1/146 (0.7) | NT | 0.2 |
| Q61H | 0/146 (/) | NT | 0.1 |
| Q61L | 0/146 (/) | NT | 0.1 |
| All mutant cases | 56/146 (38.4) | 69/153 (45.1) | 37–42.6 |
| No amplifiable DNA | 17/163 (10.4) | 10/163 (6.1) | ___ |
ASLNA, allele specific quantitative PCR using 3′-locked nucleic acid modified primers (ASLNAqPCR); NT, not tested, since ASLNAqPCR primers were designed to identify only the seven most common codon 12–13 KRAS mutations. a References [Bamford et al., 2004; Karapetis et al., 2008; Neumann et al., 2009].